These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 29573247)
1. Safety and Immunogenicity of an Egg-Cultivated Quadrivalent Inactivated Split-virion Influenza Vaccine (GC3110A) in Healthy Korean Children: a Randomized, Double-blinded, Active-controlled Phase III Study. Lee J; Lee KY; Kim JH; Kim CS; Eun BW; Kim HM; Kim DH; Hong YJ; Choi YY; Jo DS; Ma SH; Kang JH J Korean Med Sci; 2018 Mar; 33(13):e100. PubMed ID: 29573247 [TBL] [Abstract][Full Text] [Related]
2. Active-controlled phase III study of an egg-cultivated quadrivalent inactivated split-virion influenza vaccine (GC3110A) in healthy Korean children aged 6-35 months. Choi UY; Kim KH; Lee KY; Kim JH; Kim CS; Eun BW; Kim HM; Kim DH; Song SE; Jo DS; Lee J; Ma SH; Kim KN; Kang JH Vaccine; 2021 Apr; 39(15):2103-2109. PubMed ID: 33736920 [TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults. Song JY; Lee J; Woo HJ; Wie SH; Lee JS; Kim SW; Kim TH; Jung SI; Noh JY; Choi WS; Cheong HJ; Kim WJ Hum Vaccin Immunother; 2019; 15(3):710-716. PubMed ID: 30396317 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan. Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years. Kieninger D; Sheldon E; Lin WY; Yu CJ; Bayas JM; Gabor JJ; Esen M; Fernandez Roure JL; Narejos Perez S; Alvarez Sanchez C; Feng Y; Claeys C; Peeters M; Innis BL; Jain V BMC Infect Dis; 2013 Jul; 13():343. PubMed ID: 23883186 [TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects. Choi WS; Noh JY; Song JY; Cheong HJ; Wie SH; Lee JS; Lee J; Kim SW; Jeong HW; Jung SI; Kim YS; Woo HJ; Kim KH; Kim H; Kim WJ Hum Vaccin Immunother; 2017 Jul; 13(7):1653-1660. PubMed ID: 28406746 [TBL] [Abstract][Full Text] [Related]
7. A Randomized, Double-blind, Active-controlled Phase III Trial of a Cell Culture-derived Quadrivalent Inactivated Influenza Vaccine in Healthy South Korean Children and Adolescents 6 Months to 18 Years of Age. Eun BW; Lee TJ; Lee J; Kim KH; Kim DH; Jo DS; Shin SH; Kim H; Kim KH; Kim YK Pediatr Infect Dis J; 2019 Sep; 38(9):e209-e215. PubMed ID: 31335572 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: A phase 3, randomized, noninferiority study. Statler VA; Albano FR; Airey J; Sawlwin DC; Graves Jones A; Matassa V; Heijnen E; Edelman J; Marshall GS Vaccine; 2019 Jan; 37(2):343-351. PubMed ID: 30057283 [TBL] [Abstract][Full Text] [Related]
9. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. Domachowske JB; Pankow-Culot H; Bautista M; Feng Y; Claeys C; Peeters M; Innis BL; Jain V J Infect Dis; 2013 Jun; 207(12):1878-87. PubMed ID: 23470848 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study. Airey J; Albano FR; Sawlwin DC; Jones AG; Formica N; Matassa V; Leong J Vaccine; 2017 May; 35(20):2745-2752. PubMed ID: 28390934 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial. Tinoco JC; Pavia-Ruz N; Cruz-Valdez A; Aranza Doniz C; Chandrasekaran V; Dewé W; Liu A; Innis BL; Jain VK Vaccine; 2014 Mar; 32(13):1480-7. PubMed ID: 24486352 [TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a seasonal quadrivalent influenza vaccine (GC3110A) in healthy participants aged ≥ 65 years. Kim TH; Choi JH; Park SH; Yoo JH; Lee DG; Choi SM; Kim YR; Lee MS; Choo EJ; Choi HJ Vaccine; 2021 Jun; 39(27):3621-3625. PubMed ID: 33992436 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the immunogenicity and safety of quadrivalent and tetravalent influenza vaccines in children and adolescents. Huang C; Fu X; Zhou Y; Mi F; Tian G; Liu X; Wu J; Ding C; Yan D; Li L; Yang S Vaccine; 2020 Feb; 38(6):1332-1344. PubMed ID: 31948819 [TBL] [Abstract][Full Text] [Related]
14. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses. van de Witte S; Nauta J; Montomoli E; Weckx J Vaccine; 2018 Sep; 36(40):6030-6038. PubMed ID: 29709447 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age. Rodriguez Weber MA; Claeys C; Aranza Doniz C; Feng Y; Innis BL; Jain VK; Peeters M Pediatr Infect Dis J; 2014 Dec; 33(12):1262-9. PubMed ID: 25386965 [TBL] [Abstract][Full Text] [Related]
16. Randomized, single-blind, active-controlled phase I clinical trial to evaluate the immunogenicity and safety of GC3114 (high-dose, quadrivalent influenza vaccine) in healthy adults. Noh JY; Jang YS; Lee SN; Choi MJ; Yoon JG; Yu DH; Song JY; Cheong HJ; Kim WJ Vaccine; 2019 Aug; 37(36):5171-5176. PubMed ID: 31377075 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of Waning Immunity at 6 Months after Both Trivalent and Quadrivalent Influenza Vaccination in Korean Children Aged 6-35 Months. Lee JH; Cho HK; Kim KH; Lee J; Kim YJ; Eun BW; Kim NH; Kim DH; Jo DS; Kim HM; Kim YK J Korean Med Sci; 2019 Dec; 34(46):e279. PubMed ID: 31779056 [TBL] [Abstract][Full Text] [Related]
18. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial. Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6-35 months in China. Hu Y; Shao M; Hu Y; Liang Q; Jia N; Chu K; Xu L; Li J; Li C; Zhu F Hum Vaccin Immunother; 2020 Jul; 16(7):1691-1698. PubMed ID: 32347785 [TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a new trivalent inactivated split-virus influenza vaccine in healthy Korean children: a randomized, double-blinded, active-controlled, phase III study. Kang JH; Oh CE; Lee J; Lee SY; Cha SH; Kim DS; Kim HH; Lee JH; Kim JT; Ma SH; Hong YJ; Cheong HJ; Lee HJ J Korean Med Sci; 2011 Nov; 26(11):1421-7. PubMed ID: 22065897 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]